Hosted by Dr. Scott Sigman – “Dr. Brian Cole”

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com.

This episode is also brought to you by TrackableMed, grow your new patients.

We have the one and only Dr. Brian Cole for this episode. Dr. Brian Cole is an orthopedic sports medicine surgeon atMidwest Orthopaedicsat Rush and a Professor of Orthopaedics, Anatomy and Cell Biology at Rush University Medical Center. Dr. Cole is Managing Partner ofMidwest Orthopaedicsand is the Department’s Associate Chairman and the Section Head of the Cartilage Research and Restoration Center.

He’s one of the most prolific and most influential sports medicine surgeons in the world. Dr. Cole is the head team physician for the Chicago Bulls and co-team physician for the Chicago White Sox. He’s a member of every society for sports medicine orthopedics with a vast history of experience with a passion for education. This is one you’re going to enjoy!

Topics include:
-He discusses what made him decide to become a physician and the influence going into orthopedics, including residency at the Hospital for Special Surgery at Cornell Medical Center, and a Sports Medicine fellowship at the University of Pittsburgh. Dr. Cole talks about how he made his way back to Chicago after fellowship at Midwest Orthopaedics at Rush and helping to build the cartilage restoration program.

-He talks about the “private-demic” model of Rush, running it as a private practice with the benefits of being in the academic world. It’s a private independent practice that fosters entrepreneurialism.

-Dr. Cole has a passion for fellowships and can hear his devotion for the importance of mentorships. He discusses how it’s essential to positively influence the next generation through fellowships.

-We also hear about what is his work//life balance like with all of his responsibilities.

Find out more about Dr. Brian Cole here.

Also, find out more about Zynrelef here:

ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery.

-ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF’s indication.

-Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

See full prescribing information for complete boxed warning.

• Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use

• ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery

• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events

ZYNRELEF is contraindicated for:

• Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients

• Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery

WARNINGS AND PRECAUTIONS include –

Cardiovascular (CV) Thrombotic Events with NSAID Use; Gastrointestinal Bleeding, Ulceration, and Perforation with NSAID Use; Dose-Related Toxicity; Risk of Use in Patients with Impaired Cardiovascular Function; Hepatotoxicity; Hypertension; Heart Failure and Edema; Renal Toxicity and Hyperkalemia; Anaphylactic Reactions; Chondrolysis; Methemoglobinemia; Exacerbation of Asthma Related to Aspirin Sensitivity; Serious Skin Reactions; Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Hematologic Toxicity; Masking of Inflammation and Fever.

Hosted by Dr. Scott Sigman – “Brian Hodorek”

This episode is brought to you by TrackableMed. Find out more about TrackableMed here.

Brian Hodorek is the CEO and Co-Founder of Ignite Orthopedics and joins us for his great entrepreneur story. At 37 years old with his friend, they broke away from their career to start their own orthopedic implant company. He goes through the process of starting this company with his partner, the formation of the surgeon advisory board and going through the process of getting the business off the ground.

Brian’s background includes being in the orthopedic industry since 2001, with experience in R&D including Product Development Engineer, Group Manager, and Director of R&D for large and mid-size companies. Brian has focused on Upper Extremity for most of his career with a majority of work concentrated on shoulder and elbow arthroplasty.

Topics include:

-Find out why Warsaw, Indiana is important in the orthopedic implant world.

-Why Brian decided at the age of 37 to put it all on the table, take a risk and start a new company.

-How the team decided to choose their orthopedic surgeon design team to help validate their products and ideas.

-Their first product launch through DePuy Synthes with the Inhance Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System.

-Advice for those who are considering orthopreneurship.

Find out more about Brian Hodorek here.

Hosted by Dr. Scott Sigman – “Dr. Michael Ast”

This episode is brought to you by TrackableMed. To find out more about TrackableMed, go to https://www.trackablemed.com/.

This is a fantastic episode with Dr. Michael Ast, who has amazing energy and an infectious personality, you can’t help but listen to what he has to say.

Dr. Michael P. Ast is an Orthopedic Surgeon and Chief Medical Innovation Officer at HSS focusing on rapid-recovery, short-stay and outpatient joint replacement surgery includingprimary, complex and revision total joint replacement. His training includes minimally invasive hip and knee replacement, partial knee replacement, robotic surgery and computer assisted surgery.

Topics include:

-He was born and raised on blue-collar Staten island. He was a gymnast, starting at 5 years old, and attended a Division I school at Temple University. It was in his time in gymnastics when he decided to become an orthopedic surgeon. He was accepted into medical school right out of high school and was part of a 7-year program. He completed his Medical Degree at Temple University School of Medicine and returned to New York for his residency training in orthopedic surgery at North Shore-Long Island Jewish Medical Center and a fellowship in Adult Reconstruction and Joint Replacement surgery at HSS.Before returning to HSS, he previously developed and directed one of the largest and most successful outpatient joint replacement programs in the northeast.

-Dr. Ast says life is all about relationships. Don’t be afraid to network and meet people. Learn from mentors in the community and do behind-the-scenes things to elevate your game.

-How did he make the decision to go back to NYC? He initially thought they were kidding when they asked him to join HSS. Joking aside, Dr. Ast stayed in touch with his mentors to make the connection to get him back to NYC. Tune-in to hear how he was able to build his patient base after feeling like a ” teeny-tiny fish in the largest pond in the universe.”

-Dr. Ast describes his role as the Chief Medical Innovation Officer at HSS. Dr. Ast helps surgeons, who are by nature innovative, harness their ideas and figure out how to get it across the finish line to improve patient care. He describes “inside-out and outside-in” with homegrown innovation or inversely, someone bringing an idea to HSS to help get it to market.

-He closes out the interview with great advice to listeners thinking about innovation. For any back of a napkin ideas, snap pictures on your phone since it has timestamp.

Find out more about Dr. Michael Ast here.

Hosted by Dr. Scott Sigman – “Dr. Arun Hariharan”

Dr. Arun R. Hariharan is a fellowship-trained pediatric orthopedic surgeon with particular expertise in pediatric spine surgery. His main passions are in caring for children with spine-related problems such as scoliosis from a variety of conditions.

Topics include:

-Dr. Hariharan has a true passion for spine and refining his skills for pediatrics. We hear about his desire and pathway to becoming a pediatric orthopedic surgeon.

-He discusses his gratification of helping pediatrics patients and the ability to care for children with goals to get better without secondary gain. It’s interesting to hear about the differences between kids and adults with orthopedic issues. Kids just want to be fixed and go home.

-Dr. Hariharan provides advice for young orthopedic surgeons who are choosing their specialty.

Find out more about Dr. Arun Hariharan here.

Hosted by Dr. Scott Sigman – “Dr. Alexander Sah”

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com.

Dr. Alexander Sah joins for this episode from Sah Orthopaedic Associates at theInstitute for Joint Restoration in Fremont, CA. He is an orthopedic surgeon, specializing in minimally invasivehip and knee replacements,knee arthroscopy, as well as complex hip and knee revision surgeries.

Topics include:

-We hear about his patient-first emphasis with thorough and compassionate care. He has a deep commitment to the Bay Area community going home to practice at the same hospital he was born, Washington Hospital.

-We discuss his family influence in becoming a physician with his uncles, grandfather, and father practicing medicine. He completed his orthopedic training at Harvard in Boston and specialized fellowship training in minimally invasive and revision hip and knee surgery at Rush University in Chicago.

-Dr. Sah has built his brand with minimally invasive surgery where patients seek him out as a destination practice at Sah Orthopaedic Associates.

-We talk ambulatory surgery centers (ASCs) and answer these questions: Is it safe? Is it cost effective? What is the patient satisfaction?

-Dr. Sah discusses his interest in orthopedic research and remains active in publishing articles and presenting this work at national meetings. He worked with Heron Therapeutics as an expert in total knee replacement as the company developed the pivotal clinical study program to help inform FDA submissions and meet FDA guidelines for ZYNRELEF. ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery.

-ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF’s indication.

-Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

See full prescribing information for complete boxed warning.

• Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use

• ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery

• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events

ZYNRELEF is contraindicated for:

• Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients

• Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery

WARNINGS AND PRECAUTIONS include –

Cardiovascular (CV) Thrombotic Events with NSAID Use; Gastrointestinal Bleeding, Ulceration, and Perforation with NSAID Use; Dose-Related Toxicity; Risk of Use in Patients with Impaired Cardiovascular Function; Hepatotoxicity; Hypertension; Heart Failure and Edema; Renal Toxicity and Hyperkalemia; Anaphylactic Reactions; Chondrolysis; Methemoglobinemia; Exacerbation of Asthma Related to Aspirin Sensitivity; Serious Skin Reactions; Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Hematologic Toxicity; Masking of Inflammation and Fever.

Find out more about Dr. Alexander Sah here.

Hosted by Dr. Scott Sigman – “Dr. Atiba Jackson”

This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com.

If you like happy vibes with a positive patient track record, we’ve got the orthopedic surgeon for you. Meet Dr. Atiba Jackson from Dayton, OH. He is a Board-Certified Orthopedic Sports Medicine specialist, with fellowship training in sports medicine so he can provide the highest level of care for this brand of injuries. He treats complex shoulder injuries including rotator cuff, labrum, SLAP tears, instability, and dislocations. In addition to treating difficult knee injuries, including ACL tears, ligamentous injuries, meniscus tears, cartilage injuries, he also treats elbow injuries and performs elbow arthroscopy. He cares for arthritis patients, performing replacements of the shoulder, knee, and hip.

Topics include:

-His family influence in becoming an orthopedic surgeon, as his father is a family practice doctor. Dr. Jackson has strong family ties and we hear the importance of family in this episode. He also became a teenage parent, overcame the adversity and remained focused on becoming an orthopedic surgeon.

-Dr. Atiba Jackson helps train the clinical and surgical techniques at the Grandview Orthopedic Residency (DO) program. We hear about the post-grant research position they’ve developed for those in a bridge year to help them become more of a competitive applicant.

-He has social media following for promoting his private practice, Orthopedic Associates, and educating his patients. Dr. Jackson looks like Usher and uses it to his advantage when creating engaging posts.

Find out more about Dr. Atiba Jackson here.

Also, find out more about Zynrelef here:

ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery.

-ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF’s indication.

-Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

See full prescribing information for complete boxed warning.

• Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use

• ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery

• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events

ZYNRELEF is contraindicated for:

• Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients

• Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery

WARNINGS AND PRECAUTIONS include –

Cardiovascular (CV) Thrombotic Events with NSAID Use; Gastrointestinal Bleeding, Ulceration, and Perforation with NSAID Use; Dose-Related Toxicity; Risk of Use in Patients with Impaired Cardiovascular Function; Hepatotoxicity; Hypertension; Heart Failure and Edema; Renal Toxicity and Hyperkalemia; Anaphylactic Reactions; Chondrolysis; Methemoglobinemia; Exacerbation of Asthma Related to Aspirin Sensitivity; Serious Skin Reactions; Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Hematologic Toxicity; Masking of Inflammation and Fever.